These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37773555)

  • 1. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.
    Lopez-Tarruella S; Del Monte-Millán M; Roche-Molina M; Jerez Y; Echavarria Diaz-Guardamino I; Herrero López B; Gamez Casado S; Marquez-Rodas I; Alvarez E; Cebollero M; Massarrah T; Ocaña I; Arias A; García-Sáenz JÁ; Moreno Anton F; Olier Garate C; Moreno Muñoz D; Marrupe D; Lara Álvarez MÁ; Enrech S; Bueno Muiño C; Martín M
    Breast Cancer Res Treat; 2024 Jan; 203(1):163-172. PubMed ID: 37773555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
    Sánchez-Muñoz A; Vicioso L; Santonja A; Álvarez M; Plata-Fernández Y; Miramón J; Zarcos I; Ramírez-Tortosa CL; Montes-Torres J; Jerez JM; de Luque V; Llácer C; Fernández-De Sousa CE; Pérez-Villa L; Alba E
    Mod Pathol; 2018 Feb; 31(2):299-306. PubMed ID: 28984296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer.
    Dix-Peek T; Phakathi BP; van den Berg EJ; Dickens C; Augustine TN; Cubasch H; Neugut AI; Jacobson JS; Joffe M; Ruff P; Duarte RAB
    Breast Cancer Res Treat; 2023 May; 199(1):1-12. PubMed ID: 36867282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.
    Kim HK; Park KH; Kim Y; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Lee JE; Ahn JS; Im YH; Yu JH; Park YH
    Cancer Res Treat; 2019 Apr; 51(2):737-747. PubMed ID: 30189722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
    Ren X; Song Y; Zhang Y; Wu H; Chen L; Pang J; Zhou L; Shen S; Liang Z
    BMC Cancer; 2022 May; 22(1):548. PubMed ID: 35568835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study.
    Wang L; Li Q; Aushev VN; Neugut AI; Santella RM; Teitelbaum S; Chen J
    Breast Cancer; 2021 Nov; 28(6):1235-1242. PubMed ID: 34003448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting.
    Erber R; Angeloni M; Stöhr R; Lux MP; Ulbrich-Gebauer D; Pelz E; Bankfalvi A; Schmid KW; Walter RFH; Vetter M; Thomssen C; Mayr D; Klauschen F; Sinn P; Sotlar K; Stering K; Stenzinger A; Wunderle M; Fasching PA; Beckmann MW; Hoffmann O; Kimmig R; Harbeck N; Wuerstlein R; Ferrazzi F; Hartmann A
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordance of Immunohistochemistry-Based and Gene Expression-Based Subtyping in Breast Cancer.
    Holm J; Yu NY; Johansson A; Ploner A; Hall P; Lindström LS; Czene K
    JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B.
    Raj-Kumar PK; Liu J; Hooke JA; Kovatich AJ; Kvecher L; Shriver CD; Hu H
    Sci Rep; 2019 May; 9(1):7956. PubMed ID: 31138829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes.
    Caan BJ; Sweeney C; Habel LA; Kwan ML; Kroenke CH; Weltzien EK; Quesenberry CP; Castillo A; Factor RE; Kushi LH; Bernard PS
    Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):725-34. PubMed ID: 24521998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of breast cancer subtypes among African American women in the AMBER consortium.
    Allott EH; Geradts J; Cohen SM; Khoury T; Zirpoli GR; Bshara W; Davis W; Omilian A; Nair P; Ondracek RP; Cheng TD; Miller CR; Hwang H; Thorne LB; O'Connor S; Bethea TN; Bell ME; Hu Z; Li Y; Kirk EL; Sun X; Ruiz-Narvaez EA; Perou CM; Palmer JR; Olshan AF; Ambrosone CB; Troester MA
    Breast Cancer Res; 2018 Feb; 20(1):12. PubMed ID: 29409530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtyping of male breast cancer by PAM50 and immunohistochemistry: a pilot study of a consecutive Danish cohort.
    Christensen LG; Lautrup MD; Lyng MB; Möller S; Jylling AMB
    APMIS; 2020 Sep; 128(9):523-530. PubMed ID: 32579768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining breast cancer intrinsic subtypes by quantitative receptor expression.
    Cheang MC; Martin M; Nielsen TO; Prat A; Voduc D; Rodriguez-Lescure A; Ruiz A; Chia S; Shepherd L; Ruiz-Borrego M; Calvo L; Alba E; Carrasco E; Caballero R; Tu D; Pritchard KI; Levine MN; Bramwell VH; Parker J; Bernard PS; Ellis MJ; Perou CM; Di Leo A; Carey LA
    Oncologist; 2015 May; 20(5):474-82. PubMed ID: 25908555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.
    Sweeney C; Bernard PS; Factor RE; Kwan ML; Habel LA; Quesenberry CP; Shakespear K; Weltzien EK; Stijleman IJ; Davis CA; Ebbert MT; Castillo A; Kushi LH; Caan BJ
    Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):714-24. PubMed ID: 24521995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAM50 breast cancer subtypes and survival of patients in rural Ethiopia without adjuvant treatment: a prospective observational study.
    Ballé JK; Vetter M; Kenea TW; Eber-Schulz P; Reibold C; Ziegenhorn HV; Stückrath K; Wickenhauser C; Addissie A; Santos P; Kantelhardt EJ; Getachew S; Bauer M
    BMC Cancer; 2024 Sep; 24(1):1127. PubMed ID: 39256703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
    Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
    Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.
    Prat A; Cheang MC; Martín M; Parker JS; Carrasco E; Caballero R; Tyldesley S; Gelmon K; Bernard PS; Nielsen TO; Perou CM
    J Clin Oncol; 2013 Jan; 31(2):203-9. PubMed ID: 23233704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrinsic subtypes in Ethiopian breast cancer patient.
    Desalegn Z; Yohannes M; Porsch M; Stückrath K; Anberber E; Santos P; Bauer M; Addissie A; Bekuretsion Y; Assefa M; Worku Y; Taylor L; Abebe T; Kantelhardt EJ; Vetter M
    Breast Cancer Res Treat; 2022 Dec; 196(3):495-504. PubMed ID: 36282363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.